Table 3

Summary of cost-effectiveness recommendations arising from the base case analysis (threshold value: £20 000 per QALY gained)

NYHA	QRS duration <120 ms	QRS duration 120–150 ms	QRS duration >150 ms
Patients without LBBB morphology
I*	Medical therapy	ICD	Medical therapy
I	Medical therapy	ICD	Medical therapy
III	Medical therapy	Medical therapy	CRT-P
IV	Medical therapy	Medical therapy	CRT-P
Patients with LBBB morphology
I*		Medical therapy	CRT-D
II		Medical therapy	CRT-D
III		CRT-P	CRT-P
IV		CRT-P	CRT-P

*Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; NYHA, New York Heart Association; QALY, quality-adjusted life-year.